BioCorRx (BICX) Cash from Financing Activities (2010 - 2026)

BioCorRx has disclosed Cash from Financing Activities across 17 years of filings, most recently posting $505522.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $505522.0, down 19.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (up 62.82% YoY), and the FY2025 annual result was $2.3 million, up 109.96% from the prior year.
• Cash from Financing Activities came in at $505522.0 for Q1 2026 at BioCorRx, down from $699394.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $1.0 million in Q1 2022 to a low of $59158.0 in Q2 2024.
• The 5-year median for Cash from Financing Activities is $442649.0 (2023), against an average of $461684.9.
• Across the five-year window, Cash from Financing Activities slumped 89.53% in 2024 and soared 262.13% in 2025, its largest moves.
• BioCorRx's Cash from Financing Activities stood at $454662.0 in 2022, then retreated by 2.64% to $442649.0 in 2023, then dropped by 24.29% to $335113.0 in 2024, then surged by 108.7% to $699394.0 in 2025, then slipped by 27.72% to $505522.0 in 2026.
• The last three Cash from Financing Activities figures came in at $505522.0 (Q1 2026), $699394.0 (Q4 2025), and $810263.0 (Q3 2025), per Business Quant data.